Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?

ABSTRACT: Despite current guidelines and the range of available treatments, over a half of patients with asthma continue to suffer from poor symptomatic control and remain at risk of future worsening. Although a number of non-pharmacological measures are crucial for good clinical management of asthma, new therapeutic controller medications will have a role in the future management of the disease. Several long-acting anticholinergic bronchodilators are under investigation or are available for the treatment of respiratory diseases, including tiotropium bromide, aclidinium bromide, glycopyrronium bromide, glycopyrrolate and umeclidinium bromide, although none is yet licensed for the treatment of asthma. A recent Phase III investigation demonstrated that the once-daily long-acting anticholinergic bronch

SUBMITTER: Price D 

PROVIDER: S-EPMC4373380 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature